Clinical Trial Update: An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen [Phase 4]

View source ↗

Summary

An open-label Phase 4 trial evaluating the immunogenicity of the two-dose regimen of Gardasil-9 (9-valent HPV vaccine) for human papillomavirus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Boston Medical Center | Conditions: HPV Infection | Phase 4 | Status: ACTIVE_NOT_RECRUITING